Please assess the completion status of the following clinical trial:

Trial Title: Irbesartan and Atenolol in Hypertensive Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 ys old~* Male or female with no child bearing potential~* Seated blood pressure diastolic 90-115 mm Hg~* Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women~* Informed consent~Exclusion Criteria:~* Coronary artery disease, heart failure or other significant cardiac disorder~* Cerebrovascular accident within the past 6 months~* A seated systolic blood pressure above 200 mm Hg~* Significant renal disease, collagen or vascular disease, or gastrointestinal condition~* Significant allergy or intolerance to study drug~* Alcohol or drug abuse~* Uncontrolled diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Irbesartan (Type: EXPERIMENTAL): Irbesartan per os titrated to 300 mg od, 48 weeks
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol per os titrated to 100 mg od, 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).